Aimmune Therapeutics (AIMT) Reports Q3 Loss of $0.63/Share; CEO Dilly to Retire

Aimmune Therapeutics (NASDAQ: AIMT) reported Q3 EPS of ($0.63), versus $0.53 reported last year.

Aimmune also announced that CEO Stephen Dilly, M.B.B.S., Ph.D., plans to retire by the end of 2018. Aimmune will initiate a search for a successor CEO to lead the Company as it builds towards the potential commercial launch of its lead investigational product, AR101, which is currently in Phase 3 development for the treatment of peanut allergy. Dr. Dilly will continue as Aimmune’s CEO until his replacement joins the company and will be available through a transition period.

For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c